Nano-X Imaging Reports Q2 2026 Earnings with Revenue Growth but Significant Impairment Charge
Nano-X Imaging (NNOX) reported second-quarter earnings for 2026, showing $4.2 million in revenue—a 37% year-over-year increase driven by the consolidation of its Nanox Health IT business and growth across teleradiology services and AI solutions. Despite this top-line progress, the company recorded a GAAP gross loss margin of -1,051%, largely due to a $40.7 million impairment charge on its AI unit caused by declining share prices and revenue forecasts. The firm also reported an adjusted EBITDA loss of $11.3 million and non-GAAP net losses rising year-over-year to $11.6 million, partly from the inclusion of Nanox Health IT costs. To address cash flow concerns, Nano-X raised $8.5 million through capital-raising efforts and announced cost-cutting measures including a 15% workforce reduction in Israel and 67% in South Korea. Management acknowledged delays in commercialization due to operational challenges such as permitting and construction issues at clinical sites.
Tickers: $NNOX
Topics: cash runway impairment charge operational efficiency revenue